Pfizer CFO Departs to Join Consumer Goods Industry

News Summary

• Pfizer CFO Dave Denton to step down on August 15, moving to the consumer goods industry.
• The company appointed Cecile Guegan as interim CFO, effective August 16.
• CEO Albert Bourla thanked Denton for his leadership in major transactions and wished him success in his new role.

In-Depth Analysis

Pfizer announced in a press release on Thursday (June 18) that Chief Financial Officer Dave Denton will step down on August 15, citing "his acceptance of a professional opportunity in the consumer goods industry outside of the pharmaceutical sector." Denton's departure marks another significant leadership change at Pfizer, coming at a critical time as the company faces industry challenges and strategic transformation.

New York-based Pfizer has appointed Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceuticals Business, as interim Chief Financial Officer, effective August 16. The company has also initiated an internal and external search to identify Denton's permanent successor.

Pfizer Chairman and CEO Albert Bourla said in a statement: "Dave has been a steady and trusted steward of Pfizer's financial health, and we are grateful for his leadership, particularly during some of our most significant recent business transactions, including Seagen, Biohaven, and Metsera, which will benefit Pfizer for years to come. We wish him all the best as he returns to the consumer goods industry."

Denton joined Pfizer in 2022, previously serving as CFO of retailer Lowe's Companies. He took office as COVID-19 pandemic pressures eased and an early wave of executive departures in the pharmaceutical industry began to emerge. As previously reported by CFO Dive, his appointment was announced almost simultaneously with leadership changes at fellow vaccine maker Moderna.

Although Pfizer's COVID-19 vaccine and antiviral drug Paxlovid brought the company a cash reserve of $28 billion, investors were "impatient" with the subsequent performance of its "COVID franchise," according to a Bloomberg report on October 4, 2022. During Denton's tenure, Pfizer sought to diversify its business through acquisitions, including the $43 billion acquisition of Seagen and its cancer drugs in 2023. That same year, the company cut costs and staff due to declining demand for COVID products, as reported at the time by BioPharma Dive, a sister publication of CFO Dive.

In the first quarter of this year, Pfizer's oncology drugs Padcev and Lorbrena showed "strong growth," partially offsetting a 60% decline in COVID revenue. Morningstar analyst Karen Andersen wrote in a May 5 research note: "Pfizer's solid first-quarter performance lays a good foundation for achieving its full-year guidance, regardless of fluctuations in demand for fall COVID vaccines and treatments."

Despite near-term challenges, Pfizer remains a top-tier company, and its new CFO is likely to come from other well-known publicly traded companies. Josh Crist, co-managing partner of boutique executive search firm Crist Kolder, said: "This is not a company that will struggle to find CFO candidates; there will be many candidates." Crist declined to speculate on potential candidates but noted that several senior pharmaceutical finance executives have recently departed, though mostly citing retirement. These include Amgen (based in Thousand Oaks, California) CFO Peter Griffith, who announced his retirement in May, and Wolfgang Nickl, CFO of Germany's Bayer, who stepped down last month.

Guegan, 55, will serve as Pfizer's interim CFO. She has been with Pfizer for over twenty years and currently directly oversees the financial operations and reporting of the company's biopharmaceutical business. Guegan holds a master's degree in business from Brest Business School.

According to a proxy filing submitted in March, Denton's total compensation for 2025 was $9.67 million, including a salary of $1.38 million, while his total compensation for 2024 was $8.1 million. Pfizer stated in its filing with the U.S. Securities and Exchange Commission that Denton's departure is not related to the company's financial or operational performance, nor to any disagreement with the company regarding financial, operational, accounting, or reporting policies or practices.

Pfizer did not immediately respond to requests for further comment.